Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company's posted a maiden profit after receiving the first payments from licensing lead product, a Chk1 inhibitor cancer candidate, to Sierra Oncology.
Cancer drug payment nudges Sareum Holdings into maiden profit
Quick facts: Sareum Holdings PLC
Price: 1.55 GBX
Market Cap: £50.65 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE